Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen Appoints Nicolas M. Barthelemy to Board of Directors
WALTHAM, Mass., June 12, 2014 (GLOBE NEWSWIRE) - Repligen Corporation today announced that it has elected life sciences and biopharmaceutical industry veteran Nicolas M. Barthelemy to its Board of Directors. Mr. Barthelemy brings over 20 years of industry experience to the director role, most recently as President, Global Commercial Operations at Life Technologies, a multinational life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. Mr. Barthelemy is particularly accomplished in the areas of commercial expansion and global market development, supported by his strong background in biologic drug manufacturing and supply chain management. "I am pleased to welcome Nicolas Barthelemy as a fitting addition to the Repligen Board," said Walter C. Herlihy, President and Chief Executive Officer of Repligen. "Mr. Barthelemy's input will have immediate value as we expand our commercial organization to market our growing portfolio of proprietary
external link icon
Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors
WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) - Repligen Corporation today announced that it has elected to its Board of Directors John G. Cox, Executive Vice President of Pharmaceutical Operations & Technology for Biogen Idec Inc., a leading biopharmaceutical company. Mr. Cox has over 20 years of biopharmaceutical manufacturing experience and has supported the commercial launches of a number of major biologic drugs. He has a track record of implementing process changes to maximize manufacturing flexibility and throughput; this includes playing a leading role in creating the vision for Biogen Idec's "Future Factory," which aims to utilize disposable technology platforms. Separately, the Company announced that at year end, Earl Henry, M.D. will retire from the Repligen Board position that he has held since 2007. "Mr. Cox's experience and his perspective as an end user of the products developed and marketed by Repligen make him ideally suited to provide strategic guidance to our
publications icon
ZipChip Pre-Install Checklist ZCI Classic
external link icon
Repligen Appoints Jacob Johnson As Vice President Investor Relations
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, “Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth drivers for our industry and the company. Jacob has covered Repligen as a research analyst since 2019; his immediate familiarity with the company and our technologies will enable Jacob to seamlessly engage with the investor audience and pick up leadership of the IR function.” Mr. Garland added, “While
publications icon
PATsmart REBEL Preinstall Checklist
publications icon
Using PATsmart REBEL Spent Media Analysis (SMA) Kit
event icon
AAV case study: 3X titer with integrated clarification
Two case studies illustrate multi-fold upstream AAV titer increases for viral vector from HEK293 cells. In addition to productivity gains, XCell™ and TFDF® technologies clarify conditioned media for manufacturing operational simplicity. Product yield and process economics in the context of the current viral vector supply demand gap will be discussed.
external link icon
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly 30 years of relevant experience, including his current position as Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences.
Dr. Konstantinov has been directly involved in the development and commercialization of multiple biotherapeutic modalities, including monoclonal antibodies, blood factors, gene therapy vectors and exosomes. Over the past decade he has pioneered the development of integrated continuous biomanufacturing, which is becoming a strategic technological trend in the bioprocessing industry. “We are delighted to welcome Dr. Konstantinov to our board,” said Karen A. Dawes, Chairperson of the Board
event icon
An improved workflow for miniaturized pre-packed columns and automation
A workflow for automated chromatography process development created by Repligen, Tecan, and Synthace enables efficient design, deployment, and analysis of downstream purification strategies. Miniaturized OPUS® RoboColumn® Columns reduce resource demand and allow for parallelization of experiments. In conjunction with robotic liquid handling from Tecan and purpose-built automation software from Synthace, RoboColumn® Column users can optimize yield, purity, and reproducibility for expediting downstream development. The synergistic benefits of OPUS® RoboColumn® Columns, Tecan robotics, and Synthace software will be demonstrated in the context of a case study that would be unapproachable using traditional methods. May 21, 2021 53 minutes
external link icon
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support